RU97110087A - Polynucleotide Anti-Tuberculosis Vaccine - Google Patents

Polynucleotide Anti-Tuberculosis Vaccine

Info

Publication number
RU97110087A
RU97110087A RU97110087/13A RU97110087A RU97110087A RU 97110087 A RU97110087 A RU 97110087A RU 97110087/13 A RU97110087/13 A RU 97110087/13A RU 97110087 A RU97110087 A RU 97110087A RU 97110087 A RU97110087 A RU 97110087A
Authority
RU
Russia
Prior art keywords
functional equivalents
mycobacterial
antigen
polynucleotide
reactions
Prior art date
Application number
RU97110087/13A
Other languages
Russian (ru)
Other versions
RU2186109C2 (en
Inventor
А.Лиу Маргарет
Монтгомери Донна
Улмер Джеффри
Контэн Жан
Юижен Крис
Original Assignee
Мерк Энд Ко., Инк.
Н.В.Иннодженетикс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/338,992 external-priority patent/US5736524A/en
Application filed by Мерк Энд Ко., Инк., Н.В.Иннодженетикс С.А. filed Critical Мерк Энд Ко., Инк.
Publication of RU97110087A publication Critical patent/RU97110087A/en
Application granted granted Critical
Publication of RU2186109C2 publication Critical patent/RU2186109C2/en

Links

Claims (22)

1. Полинуклеотид, который после введения в ткань позвоночного индуцирует одну или несколько противомикобактериальных иммунных реакций, выбираемых среди реакций образования антител, CTL-реакций, хелперных Т-лимфоцитных реакций и защитных иммунных реакций, при этом упомянутый полинуклеотид содержит один или несколько генов, кодирующих один или несколько микобактериальных белков, или их функциональные эквиваленты, причем упомянутые гены операбельно соединены с промотором транскрипции.1. Polynucleotide, which, after introduction into the vertebral tissue, induces one or more anti-mycobacterial immune reactions, selected among the reactions of antibody formation, CTL reactions, helper T-lymphocyte reactions and protective immune reactions, wherein said polynucleotide contains one or more genes encoding one or several mycobacterial proteins, or their functional equivalents, said genes being operably linked to a transcription promoter. 2. Полинуклеотид по п. 1, отличающийся тем, что упомянутый ген кодирует белок Мусоbасtеrium tuberculosis, и его функциональные эквиваленты. 2. The polynucleotide according to claim 1, characterized in that said gene encodes a Musobacterium tuberculosis protein, and its functional equivalents. 3. Полинуклеотид по п. 2, отличающийся тем, что упомянутый ген кодирует белок, выбираемый из группы, состоящей из антигена 85А, В и/или С, и его функциональные эквиваленты. 3. The polynucleotide according to claim 2, characterized in that said gene encodes a protein selected from the group consisting of antigen 85A, B and / or C, and its functional equivalents. 4. Способ индуцирования иммунных реакций у позвоночного против микобактериальных эпитопов, включающий введение в ткань позвоночного от 1 нг до 5 мг полинуклеотида по п. 1. 4. A method of inducing immune responses in a vertebrate against mycobacterial epitopes, comprising introducing into the vertebral tissue from 1 ng to 5 mg of the polynucleotide according to claim 1. 5. Способ по п. 4, отличающийся тем, что упомянутый ген кодирует белок Мусоbасtеrium tuberculosis и его функциональные эквиваленты. 5. The method according to p. 4, characterized in that the said gene encodes a protein Musobasterium tuberculosis and its functional equivalents. 6. Способ по п. 5, отличающийся тем, что упомянутый ген кодирует белок, выбираемый из группы, состоящей из антигена 85А, В и/или С, и его функциональные эквиваленты. 6. The method according to p. 5, characterized in that said gene encodes a protein selected from the group consisting of antigen 85A, B and / or C, and its functional equivalents. 7. Вакцина для индуцирования иммунных реакций против микобактериальных антигенов, содержащая полинуклеотид по п. 1 и фармацевтически приемлемый носитель. 7. A vaccine for inducing immune responses against mycobacterial antigens containing a polynucleotide according to claim 1 and a pharmaceutically acceptable carrier. 8. Вакцина по п. 7, отличающаяся тем, что упомянутый антиген представляет собой антиген Мусоbасtеrium tuberculosis, и ее функциональные эквиваленты. 8. The vaccine according to claim 7, characterized in that said antigen is a Musobacterium tuberculosis antigen, and its functional equivalents. 9. Вакцина по п. 8, отличающаяся тем, что упомянутый антиген представляет собой белок, выбираемый из группы, состоящей из антигена 85А, В и/или С, и ее функциональные эквиваленты. 9. The vaccine according to claim 8, characterized in that said antigen is a protein selected from the group consisting of antigen 85A, B and / or C, and its functional equivalents. 10. Способ индуцирования иммунных реакций против микобактериальных антигенов, включающий введение в ткань позвоночного одного или нескольких изолированных и очищенных микобактериальных генов, выявляющих иммунную реакцию, которая предотвращает микобактериальную инфекцию и/или уменьшает интенсивность микобактериального заболевания. 10. A method of inducing immune responses against mycobacterial antigens, comprising introducing into the vertebral tissue one or more isolated and purified mycobacterial genes that detect an immune response that prevents mycobacterial infection and / or reduces the intensity of mycobacterial disease. 11. Способ по п. 10, отличающийся тем, что упомянутый ген кодирует белок Мусоbасtеrium tuberculosis, и его функциональные эквиваленты. 11. The method according to p. 10, characterized in that the said gene encodes a protein Musobasterium tuberculosis, and its functional equivalents. 12. Способ по п. 11, отличающийся тем, что упомянутый ген кодирует белок, выбираемый из группы, состоящей из антигена 85А, В и/или С, и его функциональные эквиваленты. 12. The method according to p. 11, characterized in that said gene encodes a protein selected from the group consisting of antigen 85A, B and / or C, and its functional equivalents. 13. Полинуклеотид, содержащий
а) эукариотический промотор транскрипции;
б) открытую рамку считывания, операбельно соединенную с упомянутым промотором, кодирующим один или несколько микобактериальных эпитопов, и сигнал терминации трансляции; и
b) необязательно, один или несколько операбельно связанных IRES, одну или несколько открытых рамок считывания, кодирующих один или несколько дополнительных генов, и один или несколько сигналов терминации транскрипции.13. Polynucleotide containing
a) a eukaryotic transcription promoter;
b) an open reading frame operably connected to said promoter encoding one or more mycobacterial epitopes and a translation termination signal; and
b) optionally, one or more operably linked IRES, one or more open reading frames encoding one or more additional genes, and one or more transcription termination signals. 14. Полинуклеотид по п. 13, отличающийся тем, что упомянутые в b) дополнительные гены являются иммуномодулирующими или иммуностимулирующими генами, выбираемыми из группы, состоящей из GM-CSF, ИЛ-12, интерферона и члена семейства В7 Т-клеточных костимулирующих белков. 14. The polynucleotide according to claim 13, wherein the additional genes mentioned in b) are immunomodulatory or immunostimulatory genes selected from the group consisting of GM-CSF, IL-12, interferon and a member of the B7 family of T-cell costimulatory proteins. 15. Полинуклеотид по п. 13, отличающийся тем, что упомянутый в а) микобактериальный ген кодирует белок Mycobacterium tuberculosis, и его функциональные эквиваленты. 15. The polynucleotide according to claim 13, characterized in that the mycobacterial gene mentioned in a) encodes a Mycobacterium tuberculosis protein and its functional equivalents. 16. Полинуклеотид по п. 15, отличающийся тем, что упомянутый в а) микобактериальный ген кодирует белок Мусоbасtеrium tuberculosis, выбираемый из группы, состоящей из антигена 85А, В и С, и его функциональные эквиваленты. 16. The polynucleotide according to claim 15, characterized in that the mycobacterial gene mentioned in a) encodes a Musobacterium tuberculosis protein selected from the group consisting of antigen 85A, B and C and its functional equivalents. 17. Полинуклеотид по п. 13, отличающийся тем, что упомянутые в b) дополнительные гены являются генами Мусоbасtеrium tuberculosis, выбираемыми из группы, состоящей из антигена 85А, В и С, и его функциональные эквиваленты. 17. The polynucleotide according to claim 13, wherein the additional genes mentioned in b) are Musobacterium tuberculosis genes selected from the group consisting of antigen 85A, B and C and its functional equivalents. 18. Способ лечения пациента, нуждающегося в таком лечении, полинуклеотидом, который после введения в ткань позвоночного индуцирует одну или несколько противомикобактериальных иммунных реакций, выбираемых, среди реакций образования антител, ЦТЛ-реакций, хелперных Т-лимфоцитных реакций и защитных иммунных реакций, при этом упомянутый полинуклеотид содержит ген, кодирующий один или несколько микобактериальных белков, или его функциональные эквиваленты, причем упомянутый ген операбельно соединен с промотором транскрипции. 18. A method of treating a patient in need of such treatment with a polynucleotide that, after being introduced into the vertebral tissue, induces one or more antimycobacterial immune reactions selected among antibody formation reactions, CTL reactions, helper T-lymphocyte reactions and protective immune reactions, said polynucleotide contains a gene encoding one or more mycobacterial proteins, or functional equivalents thereof, said gene being operably linked to a transcription promoter. 19. Способ по п. 18, отличающийся тем, что упомянутый ген кодирует белок Мусоbасtеrium tuberculosis, и его функциональные эквиваленты. 19. The method according to p. 18, characterized in that the said gene encodes a protein Musobasterium tuberculosis, and its functional equivalents. 20. Способ по п. 19, отличающийся тем, что упомянутый ген кодирует один или несколько белков, выбираемых из группы, состоящей из антигена 85А, В и С, и его функциональные эквиваленты. 20. The method according to p. 19, characterized in that said gene encodes one or more proteins selected from the group consisting of antigen 85A, B and C, and its functional equivalents. 21. Способ по п. 10, отличающийся тем, что упомянутым пациентом является домашнее животное или домашний скот. 21. The method according to p. 10, characterized in that the said patient is a pet or livestock. 22. Вакцина для индуцирования иммунных реакций против, микобактериальной инфекции у домашних или сельскохозяйственных животных, содержащая полинуклеотид по п. 1 и фармацевтически приемлемый носитель. 22. A vaccine for inducing immune responses against mycobacterial infection in domestic or farm animals, containing a polynucleotide according to claim 1 and a pharmaceutically acceptable carrier.
RU97110087/13A 1994-11-14 1995-11-13 Polynucleotide antituberculosis vaccine RU2186109C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US338992 1994-11-14
US08/338,992 US5736524A (en) 1994-11-14 1994-11-14 Polynucleotide tuberculosis vaccine

Publications (2)

Publication Number Publication Date
RU97110087A true RU97110087A (en) 1999-06-27
RU2186109C2 RU2186109C2 (en) 2002-07-27

Family

ID=23326996

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97110087/13A RU2186109C2 (en) 1994-11-14 1995-11-13 Polynucleotide antituberculosis vaccine

Country Status (23)

Country Link
US (2) US5736524A (en)
EP (1) EP0792358B1 (en)
JP (1) JP3881014B2 (en)
KR (1) KR970707281A (en)
CN (1) CN1171814A (en)
AT (1) ATE296882T1 (en)
AU (1) AU715067B2 (en)
CZ (1) CZ289383B6 (en)
DE (1) DE69534250T2 (en)
DK (1) DK0792358T3 (en)
ES (1) ES2242193T3 (en)
FI (1) FI972034A (en)
HU (1) HU222369B1 (en)
IL (1) IL115883A0 (en)
MX (1) MX9703606A (en)
NO (1) NO972196L (en)
NZ (1) NZ296477A (en)
PL (1) PL184839B1 (en)
PT (1) PT792358E (en)
RU (1) RU2186109C2 (en)
SK (1) SK283254B6 (en)
WO (1) WO1996015241A2 (en)
ZA (1) ZA959608B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2520078C1 (en) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) METHOD FOR OBTAINING IMMUNOGENIC COMPOSITION BASED ON Ag85A-DBD HYBRID PROTEIN AND DEXTRANE; pAg85A-DBD RECOMBINANT PLASMIDE; Escherichia coli [pREP4, pAg85A-DBD] STRAIN; Ag85A-DBD CHIMERIC PROTEIN

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (en) 1993-10-22 1996-01-12 Pasteur Institut Nucleotide vector, composition containing it and vaccine for immunization against hepatitis.
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2732895B1 (en) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTING AGENT, AS A VACCINE ADDITIVE, OR AS A MEDICINAL PRODUCT
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US20020165183A1 (en) * 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
US20070021364A1 (en) * 1995-12-13 2007-01-25 Hans Herweijer Methods for genetic immunization
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751228B1 (en) * 1996-07-19 1998-11-20 Rhone Merieux BOVINE POLYNUCLEOTIDE VACCINE FOR INTRADERMAL ROUTE
FR2751225B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux AVIAN POLYNUCLEOTIDE VACCINE FORMULA
CA2266656A1 (en) * 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
WO1998035029A1 (en) * 1997-02-07 1998-08-13 Vanderbilt University Synthetic genes for recombinant mycobacterium proteins
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
JP2002511396A (en) * 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド Needleless administration of polynucleotide preparations
DE69941545D1 (en) 1998-11-04 2009-11-26 Isis Innovation TUBERCULOSIS DIAGNOSIS TEST
US8197461B1 (en) 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
EP1165132B1 (en) * 1999-04-08 2011-10-19 Intercell USA, Inc. Dry formulation for transcutaneous immunization
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US6545127B1 (en) * 1999-06-28 2003-04-08 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP2278022A3 (en) * 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Expression vectors, transfection systems, and method of use thereof
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
CA2398207A1 (en) * 1999-12-22 2001-06-28 The Ohio State University Research Foundation Methods for protecting against lethal infection with bacillus anthracis
FR2804028B1 (en) * 2000-01-21 2004-06-04 Merial Sas IMPROVED DNA VACCINES FOR PENSION ANIMALS
US6552006B2 (en) 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US6613751B2 (en) 2000-02-23 2003-09-02 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20030130217A1 (en) * 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
JP2003531865A (en) * 2000-04-28 2003-10-28 アメリカ合衆国 Improving immunogenicity using a combination of DNA and vaccinia virus vector vaccines
US6590087B1 (en) * 2000-05-25 2003-07-08 Johns Hopkins University whmD, an essential cell division gene from mycobacteria
WO2002004018A2 (en) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
ATE429643T1 (en) 2000-07-12 2009-05-15 Agensys Inc NEW TUMOR ANTIGEN THAT CAN BE USED FOR DIAGNOSIS AND THERAPY OF BLADDER, OVARY, LUNG AND KIDNEY CANCER
EP1313850B1 (en) 2000-08-28 2008-08-06 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
EP1455816A4 (en) 2000-10-19 2007-03-28 Epimmune Inc Hla class i and ii binding peptides and their uses
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002064162A2 (en) * 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
ES2380007T3 (en) * 2001-04-06 2012-05-07 The University Of Chicago Induction by chemotherapeutic agents of the activity of the Egr-1 promoter in gene therapy
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7013940B2 (en) * 2001-04-19 2006-03-21 Michelin Recherche Et Technique S.A. Device for attenuating cavity noise in a tire and wheel
JP4338402B2 (en) 2001-05-22 2009-10-07 ユニバーシティ オブ シカゴ N4 virus single-stranded DNA-dependent RNA polymerase
WO2003015716A2 (en) * 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
BR0213965A (en) * 2001-10-26 2005-03-15 Baylor College Medicine Composition and method for altering lean and bony body mass properties in an individual
WO2003049700A2 (en) 2001-12-11 2003-06-19 Advisys, Inc. Growth hormone releasing hormone suplementation for treating chronically ill subjects
CN1617888A (en) * 2002-01-18 2005-05-18 伊诺维奥埃斯 Bispecific antibody DNA constructs for intramuscular administration
AU2003210818A1 (en) * 2002-02-01 2003-09-02 Cornell Research Foundation, Inc. Compositions and methods for treatment of infectious and inflammatory diseases
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
ATE529512T1 (en) * 2002-02-01 2011-11-15 Life Technologies Corp DOUBLE STRANDED OLIGONUCLEOTIDES
US20050267025A1 (en) * 2002-02-01 2005-12-01 Ho John L Compositions and methods for treatment of infectious and inflammatory diseases
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP1485403A4 (en) * 2002-03-15 2007-08-08 Multicell Immunotherapeutics I Compositions and methods to initiate or enhance antibody and major-histocompatibility class i or class ii-restricted t cell responses by using immunomodulatory, non-coding rna motifs
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
US7078037B2 (en) * 2002-04-19 2006-07-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
AU2003301841A1 (en) * 2002-05-01 2004-06-07 National Institutes Of Health Immunotherapy regimens in hiv-infected patients
CA2488682C (en) 2002-06-10 2014-04-01 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1575500A4 (en) * 2002-07-12 2007-01-03 Univ Johns Hopkins Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
AU2003304195B8 (en) 2002-07-15 2008-08-28 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
EP1578396A4 (en) 2002-08-12 2007-01-17 David Kirn Methods and compositions concerning poxviruses and cancer
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
DE60332377D1 (en) * 2002-10-21 2010-06-10 Eisai Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
CA2503346C (en) 2002-11-27 2014-03-18 Agensys, Inc. Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
EP1903056A3 (en) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
AU2004210975B2 (en) 2003-02-10 2008-04-10 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
JP2006522806A (en) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド Selected RNA motifs for inducing cell death and / or apoptosis
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US20070037151A1 (en) * 2003-04-28 2007-02-15 Babe Lilia M Cd4+ human papillomavirus (hpv) epitopes
DK1629088T3 (en) 2003-05-30 2012-05-07 Agensys Inc VARIABLES OF THE PROSTATASTIC CELL ANTIGEN (PSCA) AND ITS SEQUENCES
WO2004110482A1 (en) * 2003-06-13 2004-12-23 Isis Innovation Limited Improved vaccines
US20070224615A1 (en) * 2003-07-09 2007-09-27 Invitrogen Corporation Methods for assaying protein-protein interactions
CN1894581B (en) 2003-07-09 2012-02-01 生命技术公司 Method for assaying protein-protein interaction
ATE557099T1 (en) * 2003-09-05 2012-05-15 Genencor Int HPV CD8+ T-CELL EPITOPES
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
WO2005077977A2 (en) * 2004-02-11 2005-08-25 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Carcinoembryonic antigen fusions proteins and uses thereof
EP1735435A1 (en) * 2004-03-18 2006-12-27 Fred Hutchinson Cancer Research Center Methods and compositions involving s-ship promoter regions
MXPA06013834A (en) 2004-05-28 2007-03-01 Agensys Inc Antibodies and related molecules that bind to psca proteins.
US20090221440A1 (en) * 2004-07-12 2009-09-03 Board Of Regents, The University Of Texas System Methods and compositions related to identifying protein-protein interactions
WO2006135382A2 (en) 2004-08-04 2006-12-21 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
ES2534304T3 (en) 2004-11-12 2015-04-21 Asuragen, Inc. Procedures and compositions involving miRNA and miRNA inhibitor molecules
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
AP2869A (en) * 2004-12-01 2014-03-31 Aeras Global Tb Vaccine Found Electroporation of mycobacterium and overexpression of antigens in mycobacteria
CA2597404A1 (en) * 2005-02-11 2006-08-17 Merck & Co. Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
DK2325305T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
ES2385396T3 (en) 2005-02-28 2012-07-24 Oncotherapy Science, Inc. Epitopes peptides derived from vascular endothelial growth factor 1 receptor and vaccines containing these peptides
EP1863848A4 (en) 2005-03-31 2009-09-23 Agensys Inc Antibodies and related molecules that bind to 161p2f10b proteins
SI1912675T1 (en) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc B-cell reduction using cd37-specific and cd20-specific binding molecules
SI1910839T1 (en) 2005-07-27 2016-06-30 Oncotherapy Science, Inc. Colon cancer related gene tom34
AU2006279896A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating Alzheimer's disease
CA2621982C (en) * 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US7919258B2 (en) * 2005-10-07 2011-04-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Rapid tuberculosis detection method
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
BRPI0708912B8 (en) * 2006-03-14 2021-07-27 Univ Oregon Health & Science in vitro methods for detecting mycobacterium tuberculosis and cd8 expressing t cells that specifically recognize seq id no: 11 in an individual
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2008014484A1 (en) 2006-07-27 2008-01-31 University Of Maryland, Baltimore Cellular receptor for antiproliferative factor
JP5606067B2 (en) 2006-09-15 2014-10-15 オタワ ホスピタル リサーチ インスティテュート Oncolytic rhabdovirus
CN102850433B (en) 2006-10-17 2016-03-02 肿瘤疗法科学股份有限公司 For expressing the peptide vaccine of the cancer of MPHOSPH1 or DEPDC1 polypeptide
AU2007351787A1 (en) * 2006-10-20 2008-10-30 Arizona Board Of Regents For And On Behalf Of Arizona State University Modified cyanobacteria
EP2102239B1 (en) 2006-11-30 2012-04-25 Research Development Foundation Improved immunoglobulin libraries
TWI610939B (en) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 Peptide vaccines for cancers expressing tumor-associated antigens
KR20080084528A (en) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. Oncolytic vaccinia virus cancer therapy
TW201425333A (en) 2007-04-11 2014-07-01 Oncotherapy Science Inc TEM8 peptides and vaccines comprising the same
US8629245B2 (en) 2007-05-01 2014-01-14 Research Development Foundation Immunoglobulin Fc libraries
AU2008287195A1 (en) * 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP3085707B1 (en) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
KR101588736B1 (en) 2008-01-10 2016-01-26 리서치 디벨롭먼트 파운데이션 Vaccines and diagnostics for Ehrlichia chaffeensis
JP2011510308A (en) * 2008-01-23 2011-03-31 リグスホスピタル Classification of individuals suffering from cardiovascular disease based on survival prognosis found by measuring the level of biomarker YKL-40
JP5674476B2 (en) 2008-01-25 2015-02-25 ピー５３ インコーポレイテッド P53 biomarker
WO2009117439A2 (en) 2008-03-17 2009-09-24 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009117134A2 (en) * 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
PT2132228E (en) * 2008-04-11 2011-10-11 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
ES2741730T3 (en) 2008-05-19 2020-02-12 Advaxis Inc Double administration system for heterologous antigens comprising a recombinant Listeria strain attenuated by the dal / dat mutation and the ActA deletion comprising a nucleic acid molecule encoding a listeriolysin fusion protein O - prostate specific antigen
CA2954948A1 (en) 2008-06-04 2009-12-10 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
US8299232B2 (en) * 2008-07-25 2012-10-30 Department Of Biotechnology Constructing a DNA chimera for vaccine development against leishmaniasis and tuberculosis
CN107988261A (en) 2008-08-12 2018-05-04 细胞动力国际有限公司 The method for producing IPS cells
AU2009282625A1 (en) 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivatives of APF and methods of use
JP5764822B2 (en) 2008-08-27 2015-08-19 オンコセラピー・サイエンス株式会社 PRMT1 as a target gene for cancer treatment and diagnosis
AU2009302582A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
WO2010048252A1 (en) * 2008-10-23 2010-04-29 Intervet International B.V. Lawsonia intracellularis vaccines
TWI539160B (en) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Wdrpuh epitope peptides and vaccines containing the same
JP5651125B2 (en) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド MEK mutations that confer resistance to MEK inhibitors
WO2010077955A1 (en) 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
JP2012515532A (en) 2009-01-20 2012-07-12 ラモット アット テル アビブ ユニバーシティ， リミテッド MIR-21 promoter driven target cancer treatment
TWI469791B (en) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1 peptides and vaccines containing the same
JP5799394B2 (en) 2009-03-18 2015-10-28 オンコセラピー・サイエンス株式会社 NEIL3 peptide and vaccine containing the same
KR101773368B1 (en) 2009-04-03 2017-08-31 유니버시티 오브 시카고 Compositions and methods related to Protein A (SpA) variants
EP3061766B1 (en) 2009-04-28 2019-12-25 Vanderbilt University Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
TWI507204B (en) 2009-05-26 2015-11-11 Oncotherapy Science Inc Cdc45l peptides and vaccines including the same
CN102459575A (en) 2009-06-05 2012-05-16 细胞动力国际有限公司 Reprogramming t cells and hematophietic cells
WO2011025826A1 (en) 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
WO2011032180A1 (en) 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
JP2013506682A (en) * 2009-09-30 2013-02-28 セント ルイス ユニバーシティ Peptides for inducing a heterologous subtype influenza T cell response
ES2638464T3 (en) 2009-10-16 2017-10-20 The Scripps Research Institute Induction of pluripotent cells
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2510088B1 (en) 2009-12-10 2016-10-05 Ottawa Hospital Research Institute Oncolytic rhabdovirus
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
MX340392B (en) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Braf mutations conferring resistance to braf inhibitors.
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
SG10201501857YA (en) 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
CN102959076B (en) 2010-03-31 2015-09-16 斯克里普斯研究所 Reprogrammed cell
TWI538685B (en) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ect2 peptides and vaccines including the same
JP2013523818A (en) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ Compositions and methods relating to protein A (SpA) antibodies as enhancers of immune responses
WO2011126976A1 (en) 2010-04-07 2011-10-13 Vanderbilt University Reovirus vaccines and methods of use therefor
DK2560672T3 (en) 2010-04-19 2014-03-17 Res Dev Foundation RTEF-1 variants and their uses
EP3333259B1 (en) 2010-06-09 2021-02-24 Dana Farber Cancer Institute, Inc. A mek1 mutation conferring resistance to raf and mek inhibitors
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
CN103003416B (en) 2010-06-15 2016-11-16 细胞动力学国际有限公司 Inductivity pluripotent stem cell is produced from the peripheral blood of small size
CA2802087A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. A compendium of ready-built stem cell models for interrogation of biological response
CN103037885B (en) 2010-07-02 2015-08-26 芝加哥大学 The composition relevant to albumin A (SpA) variant and method
CA2804599C (en) 2010-07-06 2023-01-31 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US8785192B2 (en) 2010-07-07 2014-07-22 Cellular Dynamics International, Inc. Endothelial cell production by programming
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
JP5793194B2 (en) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Methods and compositions involving protective staphylococcal antigens
CN103501803B (en) 2010-09-22 2015-12-02 科罗拉多大学董事会 The treatment use of SMAD7
US20130267029A1 (en) 2010-10-01 2013-10-10 Fundacion Centro Nacional de Ivestigaciones Oncologicas, Carlos Manipulation of stem cell function by p53 isoforms
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
KR102703637B1 (en) 2010-12-22 2024-09-05 페이트 세러퓨틱스, 인코포레이티드 Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
AU2012204467B2 (en) 2011-01-04 2016-08-18 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
RU2539035C2 (en) * 2011-01-13 2015-01-10 Амир Закиевич Максютов Preventive or therapeutic polyepitopic anti-tuberculosis vaccine construction providing induction of cellular immune response of cd4+ or cd8+ t-lymphocytes
CA2826467C (en) 2011-02-07 2019-11-12 Research Development Foundation Engineered immunoglobulin fc polypeptides
JP6005666B2 (en) 2011-02-08 2016-10-12 セルラー ダイナミクス インターナショナル， インコーポレイテッド Production of hematopoietic progenitor cells by programming
EP2683400A4 (en) 2011-03-11 2014-09-17 Advaxis Listeria-based adjuvants
EP3406628A1 (en) 2011-04-08 2018-11-28 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2012156535A1 (en) 2011-05-19 2012-11-22 Fundación Progreso Y Salud Highly inducible dual-promoter lentiviral tet-on system
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
EP2732029B1 (en) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Methods for cell reprogramming and genome engineering
US9725490B2 (en) 2011-07-29 2017-08-08 Tokushima University ERAP1-derived peptide and use thereof
CA2842887C (en) 2011-08-12 2021-01-19 Oncotherapy Science, Inc. Mphosph1 peptides and vaccines including the same
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
WO2013026015A1 (en) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
JP2013046596A (en) * 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd New complex, medicine including the same and method of treatment for cancer
US9273102B2 (en) 2011-10-12 2016-03-01 Niels Iversen Møller Peptides derived from Campylobacter jejuni and their use in vaccination
MX355759B (en) 2011-10-28 2018-04-27 Oncotherapy Science Inc Topk peptides and vaccines including the same.
ES2886147T3 (en) 2011-12-22 2021-12-16 Interna Tech B V MiRNAs for the treatment of head and neck cancer
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP2844275B1 (en) 2012-04-26 2020-05-13 University of Chicago Staphylococcal coagulase antigens and methods of their use
CA2910320A1 (en) 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
JP6255594B2 (en) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 LY6K epitope peptide of Th1 cell and vaccine containing the same
JP6259983B2 (en) 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Th1 cell KIF20A epitope peptide and vaccine containing the same
MX362912B (en) 2012-09-11 2019-02-22 Oncotherapy Science Inc Ube2t peptides and vaccines containing the same.
WO2014065945A1 (en) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Antibodies with engineered igg fc domains
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
JP6475172B2 (en) 2013-02-20 2019-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Rat genetic recombination
RU2684211C2 (en) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Vaccine composition
WO2014130770A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US10086093B2 (en) 2013-02-28 2018-10-02 The General Hospital Corporation miRNA profiling compositions and methods of use
US10456448B2 (en) 2013-03-08 2019-10-29 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics
TWI658049B (en) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2 peptides and vaccines containing the same
EP2968506B1 (en) * 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
ES2702622T3 (en) 2013-03-27 2019-03-04 Immunovaccine Technologies Inc Method to improve the effectiveness of a survivin vaccine in the treatment of cancer
AU2014317861B2 (en) 2013-09-09 2019-11-28 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
WO2015070009A2 (en) 2013-11-08 2015-05-14 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
WO2015070050A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
WO2015082536A1 (en) 2013-12-03 2015-06-11 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
EP3099719B1 (en) 2014-01-29 2020-04-01 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
WO2015123561A2 (en) 2014-02-14 2015-08-20 University Of Utah Research Foundation Methods and compositions for inhibiting retinopathy of prematurity
CA2940765A1 (en) 2014-02-25 2015-09-03 Research Development Foundation Sty peptides for inhibition of angiogenesis
EP3114214B1 (en) 2014-03-04 2023-11-01 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
CN111925431A (en) 2014-08-04 2020-11-13 肿瘤疗法科学股份有限公司 KOC 1-derived peptides and vaccines containing the same
US10676514B2 (en) 2014-08-04 2020-06-09 Oncotherapy Science, Inc. CDCA1-derived peptide and vaccine containing same
ES2856834T3 (en) 2014-08-04 2021-09-28 Oncotherapy Science Inc URLC10 derived peptide and vaccine containing the same
US20180363070A9 (en) 2014-08-12 2018-12-20 Univ Wayne State Systems and methods to detect stem cell stress and uses thereof
US20180169211A1 (en) 2014-11-13 2018-06-21 Evaxion Biotech Aps Peptides derived from acinetobacter baumannii and their use in vaccination
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
WO2016113252A2 (en) 2015-01-12 2016-07-21 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae
EP3250675A1 (en) 2015-01-28 2017-12-06 SABIC Global Technologies B.V. Methods and compositions for high-efficiency production of biofuel and/or biomass
CA2976236A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
WO2016134293A1 (en) 2015-02-20 2016-08-25 Baylor College Of Medicine p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
EP4276106A3 (en) 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
WO2017005670A1 (en) 2015-07-04 2017-01-12 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3 binding polypeptides
MX2018004308A (en) 2015-10-08 2018-05-01 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same.
KR20180055918A (en) 2015-10-16 2018-05-25 페이트 세러퓨틱스, 인코포레이티드 Platform for the induction and maintenance of ground-state versatility
DK3365435T3 (en) 2015-10-20 2021-04-06 Fujifilm Cellular Dynamics Inc Production of multi-lineage hematopoietic precursor cells with genetic programming
MX2018005274A (en) 2015-10-30 2019-09-19 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells.
LT3370733T (en) 2015-11-02 2021-10-25 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
PL3373968T3 (en) 2015-11-09 2024-08-05 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
EP3419654B1 (en) 2016-02-22 2022-04-27 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
CA3019635A1 (en) 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
WO2017216384A1 (en) 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination targeting ichthyophthirius multifiliis
US11091775B2 (en) * 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2017220787A1 (en) 2016-06-24 2017-12-28 Evaxion Biotech Aps Vaccines against aearomonas salmonicida infection
JP7099967B2 (en) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション Elimination of Proliferative Cells from Stem Cell-Derived Grafts
WO2018015575A1 (en) 2016-07-22 2018-01-25 Evaxion Biotech Aps Chimeric proteins for inducing immunity towards infection with s. aureus
WO2018035429A1 (en) 2016-08-18 2018-02-22 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
CN109963590B (en) 2016-09-02 2024-03-15 加利福尼亚大学董事会 Methods and compositions involving interleukin-6 receptor alpha binding single chain variable fragment
EP3523423B1 (en) 2016-10-05 2024-07-31 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to hla homozygous immune cells
AU2017340634B2 (en) 2016-10-05 2022-06-02 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with MECP2 disruption
AU2017375958A1 (en) 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
EP3565576A1 (en) 2017-01-05 2019-11-13 Evaxion Biotech ApS Vaccines targeting pseudomonas aeruginosa
KR102668891B1 (en) 2017-04-18 2024-05-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 Antigen-specific immune effector cells
AU2018358016A1 (en) 2017-11-03 2020-05-07 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
US11612618B2 (en) 2017-11-14 2023-03-28 Henry Ford Health System Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
JP2021509815A (en) 2018-01-05 2021-04-08 オタワ ホスピタル リサーチ インスティチュート Modified vaccinia vector
WO2019145399A1 (en) 2018-01-24 2019-08-01 Evaxion Biotech Aps Vaccines for prophylaxis of s. aureus infections
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
CA3133899A1 (en) 2018-03-30 2019-10-03 University Of Geneva Micro rna expression constructs and uses thereof
TW202023581A (en) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 Cdca1-derived peptide and vaccine containing same
JP7450945B2 (en) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド Cardiac cell reprogramming using myocardin and ASCL1
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
WO2020083904A1 (en) 2018-10-22 2020-04-30 Evaxion Biotech Aps Vaccines targeting m. catharrhalis
WO2020111167A1 (en) 2018-11-30 2020-06-04 国立大学法人徳島大学 Therapeutic agent for breast caner comprising big3-phb2 interaction-inhibiting peptide derived from phb2
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
US20220143168A1 (en) 2019-02-27 2022-05-12 Evaxion Biotech A/S Vaccines targeting H. influenzae
SG10201905939WA (en) 2019-06-26 2021-01-28 Cell Mogrify Australia Pty Ltd Cell culture methods and compositions
EP3997226A1 (en) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
EP3999546A1 (en) 2019-07-19 2022-05-25 The Children's Hospital of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
EP4045044A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California Plxdc activators and their use in the treatment of blood vessel disorders
KR102237349B1 (en) 2019-10-23 2021-04-07 한국과학기술연구원 Pharmaceutical composition for the treatment or prevention of nicotine addiction and withdrawal comprising miRNA
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4087593A1 (en) 2020-01-06 2022-11-16 Evaxion Biotech A/S Vaccines targeting neisseria gonorrhoeae
EP4114421A1 (en) 2020-03-02 2023-01-11 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed micrornas
JP2023520359A (en) 2020-03-25 2023-05-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム Reporter system for radionuclide imaging
EP4157864A1 (en) 2020-05-27 2023-04-05 Antion Biosciences SA Adapter molecules to re-direct car t cells to an antigen of interest
IL298085A (en) 2020-05-29 2023-01-01 Fujifilm Cellular Dynamics Inc Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
MX2022015002A (en) 2020-05-29 2023-03-03 Fujifilm Cellular Dynamics Inc Bilayer of retinal pigmented epithelium and photoreceptors and use thereof.
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
EP4291216A1 (en) 2021-02-09 2023-12-20 University of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
US20240122865A1 (en) 2021-02-19 2024-04-18 Pfizer Inc. Methods of Protecting RNA
BR112023021993A2 (en) 2021-05-03 2024-02-20 Astellas Inst For Regenerative Medicine METHODS FOR GENERATING ENDOTHELIAL CELLS FROM THE MATURE CORNEA
CN117716020A (en) 2021-05-07 2024-03-15 安斯泰来再生医药协会 Method for producing mature hepatocytes
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
EP4366762A1 (en) 2021-07-05 2024-05-15 Evaxion Biotech A/S Vaccines targeting neisseria gonorrhoeae
EP4436595A1 (en) 2021-11-22 2024-10-02 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
US20230295661A1 (en) 2022-03-16 2023-09-21 University Of Houston System Persistent hsv gene delivery system
GB202205265D0 (en) 2022-04-11 2022-05-25 Mogrify Ltd Cell conversion
WO2023213393A1 (en) 2022-05-04 2023-11-09 Evaxion Biotech A/S Staphylococcal protein variants and truncates
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
WO2023239940A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
WO2024186630A1 (en) 2023-03-03 2024-09-12 Henry Ford Health System Use of extracellular vesicles for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
DE69034078T2 (en) * 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression of exogenous polynucleotide sequences in vertebrates
ATE189684T1 (en) * 1989-09-19 2000-02-15 Innogenetics Nv RECOMBINANT POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING THEREFOR AND THEIR USE IN TUBERCULOSIS DIAGNOSIS
EP0499003A1 (en) * 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
IL108915A0 (en) * 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AU6280596A (en) * 1995-06-15 1997-01-15 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis dna sequences encoding immunostimlatory peptides
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2520078C1 (en) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) METHOD FOR OBTAINING IMMUNOGENIC COMPOSITION BASED ON Ag85A-DBD HYBRID PROTEIN AND DEXTRANE; pAg85A-DBD RECOMBINANT PLASMIDE; Escherichia coli [pREP4, pAg85A-DBD] STRAIN; Ag85A-DBD CHIMERIC PROTEIN

Similar Documents

Publication Publication Date Title
RU97110087A (en) Polynucleotide Anti-Tuberculosis Vaccine
KR970707281A (en) A polynucleotide tuberculosis vaccine
Eugui et al. Genetically restricted cell-mediated cytotoxicity in cattle immune to Theileria parva
Nussenzweig et al. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites
US5733778A (en) A2 gene of leishmania which is differentially-expressed in amastigote form
CA2293489A1 (en) Inhibitors of dna immunostimulatory sequence activity
Melby et al. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection
US4931275A (en) Anti-tumor vaccines and their preparation
WO1985000976A1 (en) Method and materials for development of immunological responses protective against malarial infection
Roberts et al. Congenital toxoplasmosis in the Balb/c mouse: prevention of vertical disease transmission and fetal death by vaccination
Schofield et al. Lack of Ir gene control in the immune response to malaria. I. A thymus-independent antibody response to the repetitive surface protein of sporozoites.
Teixeira Chagas' disease: trends in immunological research and prospects for immunoprophylaxis.
Leff et al. Cross immunity in channel catfish, Ictalurus punctatus (Rafinesque), against two immobilization serotypes of Ichthyophthirius multiftliis (Fouquet).
US20080107645A1 (en) Neospora caninum isolate
Innes et al. Analysis of in vivo immune responses during Toxoplasma gondii infection using the technique of lymphatic cannulation
Fakae et al. The intensity and duration of primary Heligmosomoides polygyrus infection in TO mice modify acquired immunity to secondary challenge
ONAH et al. Induction of CD4+ CD8+ double positive T cells and increase in CD5+ B cells in efferent lymph in sheep infected with Trypanosoma evansi
Brown et al. Modulation of host immune responses by protozoal DNA
Fitzgerald Syphilis vaccine: up-regulation of immunogenicity by cyclophosphamide, Ribi adjuvant, and indomethacin confers significant protection against challenge infection in rabbits
AU683030B2 (en) Immunization against (neisseria gonorrhoeae) and (neisseria meningitidis)
WO1985000975A1 (en) Method and materials for development of immunological responses protective against malarial infection
Smelt et al. Failure to induce delayed-type hypersensitivity to Mycobacterium leprae in long-term treated lepromatous leprosy patients.
Frankenburg et al. Cell-mediated responses and protection elicited by a carbohydrate-lipid-containing fraction extracted from Leishmania major promastigotes
Sharp Studies of cross-strain protection between two strains of Babesia microti and the effects of several immunomodulators on these two strains
Mogil et al. An immunogenic antigen of murine Plasmodium yoelii 17X associates with class I MHC glycoproteins.